BioGend Therapeutics Co., Ltd. received notification from the Thai FDA that "Revocart" was approved to obtain a Thai medical device license. The company received notification from the Thailand FDA that Revocart was approved to obtain a Thailand medical device license. The company will seek dealers in Thailand to be responsible for the local promotion and sales of Revocart.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
36.7 TWD | -0.81% | +0.69% | -4.05% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-4.05% | 140M | |
+45.86% | 54.63B | |
-6.71% | 39.92B | |
+37.07% | 38.82B | |
+13.27% | 26.86B | |
-11.17% | 26.22B | |
-21.63% | 18.78B | |
+25.48% | 12.21B | |
+0.31% | 12.16B | |
+25.74% | 11.94B |
- Stock Market
- Equities
- 6733 Stock
- News BioGend Therapeutics Co., Ltd.
- BioGend Therapeutics Co., Ltd. Receives Notification from the Thai FDA That Revocart to Obtains A Thai Medical Device License